February 3, 2020 07:19 AM EST
R&D

Bris­tol-My­ers with­draws Op­di­vo/Yer­voy lung can­cer EU ap­pli­ca­tion — but oth­ers are in­com­ing

Natalie Grover

Reporter

Ear­ly in 2019, Bris­tol-My­ers Squibb re­scind­ed an FDA ap­pli­ca­tion to mar­ket its check­point in­hibitor Op­di­vo in com­bi­na­tion with its CT­LA-4 ther­a­py Yer­voy for front­line …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

No­var­tis, Ab­b­Vie and PhRMA se­cure 340B court win in West Vir­ginia

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

A service from the Financial Times